Welcome to our dedicated page for Pavmed news (Ticker: PAVM), a resource for investors and traders seeking the latest updates and insights on Pavmed stock.
PAVmed Inc. reports recurring business updates as a diversified commercial-stage medical technology company operating across medical devices, diagnostics and digital health. Company updates commonly address financial results, capital-structure actions, medical device portfolio development and subsidiary activity.
News also covers Lucid Diagnostics, PAVmed's commercial-stage cancer prevention diagnostics subsidiary, including EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device activity for patients at risk of esophageal precancer and cancer. Other recurring subjects include Veris Health digital health programs, the Veris Cancer Care Platform, implantable physiological monitor development and PAVmed's endoscopic esophageal imaging technology through Octeris.
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) will hold a business update conference call on May 21, 2020, at 4:30 PM ET. CEO Lishan Aklog and CFO Dennis McGrath will discuss the company's Q1 2020 financial results and upcoming milestones. PAVmed is known for its innovative medical device solutions across various fields, including GI health and minimally invasive interventions. The company leverages a unique business model for rapid product commercialization. Live access to the call is available via phone or webcast on its investor relations website.